EquitiesIndia.com

Healthcare · Drug Manufacturers - Specialty & Generic

NATCO Pharma Ltd.

NATCOPHARM

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

NSE: NATCOPHARMOfficial website ↗

Key metrics

Market Cap

₹19,777 cr

P/E Ratio

12.71x

P/B Ratio

2.6x

ROE

24.79%

ROCE

29.27%

Debt / Equity

0.04x

Net Margin

42.74%

Dividend Yield

59%

EPS

₹105.26

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 50.55%FII: 11.37%Public: 38.08%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about NATCO Pharma Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.